Although this is still an uncertain subject, it may be beneficial to identify the AD-prone population, such as APOE ɛ4 carriers, and commence AD treatment at initial stages of the disease, or even before any symptoms arise. The gene discussed is APOE; the disease is Alzheimer disease.